Brian Stuglik. Verastem

Ve­rastem taps board di­rec­tor and Eli Lil­ly vet Bri­an Stug­lik to right the com­mer­cial boat

When Ve­rastem part­ed ways with CEO Robert For­rester days ago, the board in­di­cat­ed that they would be look­ing for a suc­ces­sor with the com­mer­cial chops to bright­en up the fu­ture of its PI3K drug du­velis­ib.

Turns out they had a can­di­date right among them.

Bri­an Stug­lik — a di­rec­tor of two years — has now been in­stalled at the helm. The Eli Lil­ly vet be­gan tak­ing a strate­gic over­sight and ad­vi­so­ry role to Ve­rastem’s com­mer­cial group in May, the com­pa­ny added, in ad­di­tion to chair­ing the com­pen­sa­tion com­mit­tee.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.